Gonadotropin releasing hormone antagonists and cryopreservation outcome: A review

被引：3

作者：

Nikolettos N. ^{[1
]}

Asimakopoulos B. ^{[1
]}

Simopoulou M. ^{[1
]}

Al-Hasani S. ^{[2
]}

Diedrich K. ^{[2
]}

机构：

[1] Lab. of Reproductive Physiology-IVF, Faculty of Medicine, Democritus University of Thrace, 68100 Dragana, Alexandroupolis

[2] Department of Obstetrics, Medical University Lübeck, 23538 Lübeck

来源：

Archives of Gynecology and Obstetrics | 2004年 / 270卷 / 2期

关键词：

Cryopreservation; GnRH-agonist; GnRH-antagonist; In-vitro fertilisation;

D O I：

10.1007/s00404-003-0597-3

中图分类号：

学科分类号：

摘要：

Review: The outcome of freeze-thaw cycles with pronuclear stage oocytes or embryos, derived from collecting cycles stimulated with gonadotropin-releasing hormone (GnRH)-antagonists' protocols, was reviewed. Conclusion: The viability of cryopreserved pronuclear stage oocytes and embryos, the quality of transferred embryos and the pregnancy rates of the freeze-thaw cycles seem to be satisfactory regardless of the type and dose of GnRH-antagonist.

引用

页码：69 / 73

页数：4

共 52 条

[41]

Olivennes F., Fanchin R., Bouchard P., De Ziegler D., Taieb J., Selva J., Frydman R., The single or dual administration of the gonadotrophin-releasing hormone antagonist Cetrorelix in an in vitro fertilization-embryo transfer programme, Fertil Steril, 62, pp. 468-476, (1994)

[42]

Olivennes F., Fanchin R., Bouchard P., Taieb J., Selva J., Frydman R., Scheduled administration of a gonadotrophin-releasing hormone antagonist (Cetrorelix) on day 8 of in vitro fertilization cycles: A pilot study, Hum Reprod, 10, pp. 1382-1386, (1995)

[43]

Olivennes F., Belaisch-Allart J., Emperaire J.C., Dechaud H., Alvarez S., Moreau L., Nicollet B., Zorn J.R., Bouchard P., Frydman R., Prospective, randomized, controlled study of in-vitro fertilization-embryo transfer with a single dose of a luteinizing hormone-releasing hormone (LHRH) antagonist (Cetrorelix) or a depot formula of an LH-RH agonist (Triptoreline), Fertil Steril, 73, pp. 314-320, (2000)

[44]

Ortmann O., Diedrich K., Pituitary and extrapituitary actions of gonadotrophin-releasing hormone and its analogues, Hum Reprod, 14, SUPPL. 1, pp. 194-206, (1999)

[45]

Ortmann O., Weiss J.M., Diedrich K., Embryo implantation and GnRH antagonists. Ovarian actions of GnRH antagonists, Hum Reprod, 16, pp. 608-611, (2001)

[46]

Pinski J., Reile H., Halmos G., Groot K., Schally A.V., Inhibitory effects of analogs of luteinizing hormone-releasing hormone on the growth of the androgen-independent dunning R-3327-AT-1 rat prostate cancer, Int J Cancer, 59, pp. 51-55, (1994)

[47]

Reissmann T., Felberbaum R., Diedrich K., Engel J., Comaru-Schally A.M., Schally A.V., Development and applications of luteinizing hormone-releasing hormone antagonists in the treatment of infertility: An overview, Hum Reprod, 10, pp. 1974-1981, (1995)

[48]

Sadler S.E., Type III phosphodiesterase plays a necessary role in the growth-promoting actions of insulin, IGF-I and Ha p21ras in Xenopus laevis oocytes, Mol Endocrinol, 5, pp. 1939-1946, (1991)

[49]

Seelig A.S., Al-Hasani S., Katalinic A., Schopper B., Sturm R., Diedrich K., Ludwig M., Comparison of cryopreservation outcome with gonadotropin-releasing hormone agonists or antagonists in the collecting cycle, Fertil Steril, 77, pp. 472-475, (2002)

[50]

Shirahige Y., Cook C.B., Pinski J., Et al., Treatment with luteinizing hormone-releasing hormone antagonist SB-75 decreases levels of epidermal growth factor receptor and its mRNA in OV-1063 human epithelial ovarian cancer xenografts in nude mice, Int J Oncol, 5, pp. 3052-3060, (1994)

← 1 2 3 4 5 6 →